Early Atrial Fibrillation Ablation for Stroke Prevention in Patients with High Comorbidity Burden (EASThigh-AFNET 11)

NARECRUITING

EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial). The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.

Study details:

Atrial Fibrillation (AF) is associated with high morbidity and mortality. Even on optimal anticoagulation and therapy of concomitant conditions, many patients with AF suffer cardiovascular events, especially heart failure events, stroke, and cardiovascular death. Most of these events occur in elderly patients with comorbidities.

Early rhythm control, mainly delivered using antiarrhythmic drugs, reduces AF-related complications when added to anticoagulation, rate control, and treatment of comorbidities when compared to current practice that offers rhythm control mainly to reduce symptoms. The outcome-reducing effect of early rhythm control is most pronounced in patients with multiple comorbidities, quantified by a CHA2DS2-VASc score ≥ 4. Attaining sinus rhythm is the key mediator for the outcome-reducing effect of early rhythm control.

Atrial fibrillation ablation controls the rhythm better than drug-based rhythm control, avoids long-term antiarrhythmic drug treatment, thus reducing polypharmacy, and may therefore be the ideal rhythm control treatment in patients with AF and a high comorbidity burden. This hypothesis needs testing. The investigator-initiated EASThigh-AFNET 11 trial evaluates the effectiveness and safety of early atrial fibrillation ablation in patients with recently diagnosed AF and a high comorbidity burden.

EASThigh-AFNET 11 is a Treatment Strategy trial randomizing 2312 patients with AF and a high comorbidity burden to early atrial fibrillation ablation or usual care to achieve a fixed number of primary endpoint events of n=527. All therapies are clinically approved. The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for worsening of heart failure.

The primary safety outcome is a composite of all-cause death and serious complications of AF therapy. Secondary outcome parameters address safety, patient reported outcomes and cognitive function. EASThigh-AFNET 11 was recommended for funding by the Expert Advisory Panel of the Global Cardiovascular Research Funders Forum (GCRFF).

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. AF first diagnosed within 2 years prior to enrolment and documented in body surface ECG
  2. High comorbidity estimated by CHA2DS2-VASc score of 4 or more
  3. Patient suitable for ablation using cryoballoon ablation systems from Medtronic
  4. Age ≥ 18 years
  5. Provision of signed informed consent

Exclusion criteria

  1. Any disease that limits life expectancy to less than 1 year.
  2. Participation in another clinical trial, either within the 3 months prior to enrolment or still on-going (participation in potential sub-studies connected to this trial is permitted).
  3. Previous participation in EASThigh-AFNET 11.
  4. Pregnant women.
  5. Breastfeeding women.
  6. Drug abuse or clinically manifest alcohol abuse.
  7. Prior AF ablation or surgical therapy of AF.
  8. Patients not suitable for AF ablation.
  9. Patients with a history of stroke which occurred within 3 months prior to enrolment.
  10. Valve disease requiring specific therapy.
  11. Clinically manifested thyroid dysfunction requiring therapy.

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

PREVENTION

phase

Phase

    NA

trial

Study ID

NCT06324188

Intervention or treatment

OTHER: Early atrial fibrillation ablation

OTHER: Usual Care

Conditions

  • Atrial Fibrillation
  • Condition: Atrial Fibrillation

  • OTHER: Early atrial fibrillation ablation and other drugs

  • Multiple Locations, Australia

  • Sponsor: Atrial Fibrillation Network

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Several sites

Select from list below to view details:

  • Several sites

    Multiple Locations, Australia

Loading map...

Who is running the clinical trial?

AFN

Atrial Fibrillation Network

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
OTHER: Early atrial fibrillation ablation
  • Not Specified
Other: Early atrial fibrillation ablation
    OTHER: Usual Care
    • Not Specified
    Other: Usual Care

      What is the study measuring?

      Primary Outcome

      MeasureDescriptionTime Frame
      Composite of cardiovascular complications related to AFIt is defined as time from randomisation to the first occurrence of a composite of cardiovascular death, stroke (either ischemic or hemorrhagic), or hospitalisation for worsening of heart failure.Throughout study completion, estimated at a mean of 4 years
      The primary safety outcome is a composite of all-cause death and serious complications of AF therapy.Serious Adverse Events (SAEs), including primary and secondary outcome parameters if based on clinical events, will be adjudicated by the independent Clinical Event Committee (CEC) according to standardised definitions given in the CEC charter.Throughout study completion, estimated at a mean of 4 years

      Secondary Outcome

      MeasureDescriptionTime Frame
      Number of nights spent in hospitalNot SpecifiedThroughout study completion, estimated at a mean of 4 years
      Time from randomisation to first occurrence of each of the individual components of the primary outcomeNot SpecifiedThroughout study completion, estimated at a mean of 4 years
      All-cause deathNot SpecifiedThroughout study completion, estimated at a mean of 4 years
      Serious adverse events related to AF therapyNot SpecifiedThroughout study completion, estimated at a mean of 4 years
      Time from randomisation to first cardiovascular hospitalisationNot SpecifiedThroughout study completion, estimated at a mean of 4 years
      Number of cardiovascular hospitalisations (over-night stay)Not SpecifiedThroughout study completion, estimated at a mean of 4 years
      Changes in left ventricular ejection fractionNot Specifiedcomparing baseline with 24 months follow up (FU)
      Changes in quality of lifeassessed by EQ-5D-5Lcomparing baseline with 12 and 24 months FU
      Changes in quality of lifeassessed by AFEQTcomparing baseline with 12 and 24 months FU
      Changes in cognitive functionassessed by Montreal-Cognitive-Assessment-Testcomparing baseline with 24 months FU
      Cardiac rhythm statussinus rhythm compared to AFat 12 and 24 months FU
      AF patternNot Specifiedat 12 and 24 months FU
      Time from randomisation to first clinical recurrence of AFNot SpecifiedThroughout study completion, estimated at a mean of 4 years
      Time from randomisation to first progression of AFi. e. from paroxysmal to persistent or longstanding persistent or permanent and each of these componentsThroughout study completion, estimated at a mean of 4 years
      Are you running this trial?If you're a clinic or sponsor, you can claim this study.

      References

      Clinical Trials Gov: Early Atrial Fibrillation Ablation for Stroke Prevention in Patients with High Comorbidity Burden (EASThigh-AFNET 11)

      Other trials to consider

      Loading suggested trials...

      Top searched conditions